SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000947871-24-000292
Filing Date
2024-03-20
Accepted
2024-03-20 17:24:26
Documents
2
Group Members
GHIATH M. SUKHTIAN

Document Format Files

Seq Description Document Type Size
1 UNDER THE SECURITIES EXCHANGE ACT OF 1934 ss3153634_sc13da.htm SC 13D/A 68353
2 JOINT FILING AGREEMENT ss3153634_ex9901.htm EX-99.1 4870
  Complete submission text file 0000947871-24-000292.txt   75006
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Subject) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: SC 13D/A | Act: 34 | File No.: 005-89495 | Film No.: 24768662
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD. 190 ELGIN AVENUE GEORGE TOWN E9 KYI-9007
Business Address C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD. 190 ELGIN AVENUE GEORGE TOWN E9 KYI-9007 962 6 582 7999
GMS Ventures & Investments (Filed by) CIK: 0001804598 (see all company filings)

IRS No.: 000000000
Type: SC 13D/A